Universität zu Köln

Mayer, Marcel ORCID: 0000-0001-9963-1109, Nachtsheim, Lisa, Hoffmann, Franziska ORCID: 0000-0002-6872-924X, von Eggeling, Ferdinand ORCID: 0000-0002-8062-6999, Guntinas-Lichius, Orlando ORCID: 0000-0001-9671-0784, Prinz, Johanna, Klussmann, Jens Peter ORCID: 0000-0002-8223-7954, Quaas, Alexander, Arolt, Christoph and Wolber, Philipp ORCID: 0000-0001-9019-2840 (2022). CD138 Is Expressed in Different Entities of Salivary Gland Cancer and Their Lymph Node Metastases and Therefore Represents a Potential Therapeutic Target. Int. J. Mol. Sci., 23 (16). BASEL: MDPI. ISSN 1422-0067

Full text not available from this repository.

Abstract

Advanced salivary gland carcinomas (SGC) often lack therapeutic options. Agents targeting CD138 have recently shown promising results in clinical trials for multiple myeloma and a preclinical trial for triple-negative breast cancer. Immunohistochemistry for CD138 was performed for all patients who had undergone primary surgery for SGC with curative intent. Findings were validated using matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS) imaging. Overall, 111 primary SGC and 13 lymph node metastases from salivary duct carcinomas (SaDu) were evaluated. CD138 expression was found in 60% of all SGC with differing expression across entities (p < 0.01). A mean of 25.2% of the tumor cells in mucoepidermoid carcinoma (MuEp) were positive, followed by epithelial-myoepithelial carcinoma (20.9%), acinic cell carcinoma (16.0%), and SaDu (15.2%). High-/intermediate-grade MuEp showed CD138 expression in a mean of 34.8% of tumor cells. For SaDu, lymph node metastases showed CD138 expression in a mean of 31.2% of tumor cells which correlated with CD138 expression in their primaries (p = 0.01; Spearman's rho = 0.71). MALDI-MS imaging confirmed the presence of the CD138 protein in SGC. No significant association was found between clinicopathological data, including progression-free survival (p = 0.50) and CD138 expression. CD138 is expressed in the cell membrane of different entities of SGC and SaDu lymph node metastases and therefore represents a potential target for CD138 targeting drugs.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Mayer, Marcel UNSPECIFIED orcid.org/0000-0001-9963-1109 UNSPECIFIED Nachtsheim, Lisa UNSPECIFIED UNSPECIFIED UNSPECIFIED Hoffmann, Franziska UNSPECIFIED orcid.org/0000-0002-6872-924X UNSPECIFIED von Eggeling, Ferdinand UNSPECIFIED orcid.org/0000-0002-8062-6999 UNSPECIFIED Guntinas-Lichius, Orlando UNSPECIFIED orcid.org/0000-0001-9671-0784 UNSPECIFIED Prinz, Johanna UNSPECIFIED UNSPECIFIED UNSPECIFIED Klussmann, Jens Peter UNSPECIFIED orcid.org/0000-0002-8223-7954 UNSPECIFIED Quaas, Alexander UNSPECIFIED UNSPECIFIED UNSPECIFIED Arolt, Christoph UNSPECIFIED UNSPECIFIED UNSPECIFIED Wolber, Philipp UNSPECIFIED orcid.org/0000-0001-9019-2840 UNSPECIFIED
URN:	urn:nbn:de:hbz:38-666189
DOI:	10.3390/ijms23169037
Journal or Publication Title:	Int. J. Mol. Sci.
Volume:	23
Number:	16
Date:	2022
Publisher:	MDPI
Place of Publication:	BASEL
ISSN:	1422-0067
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language MULTIPLE-MYELOMA; CARCINOMAS; HEAD; CELLS Multiple languages Biochemistry & Molecular Biology; Chemistry, Multidisciplinary Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/66618